TY - JOUR AU - Thunyaharn, Sudaluck AU - Santimaleeworagun, Wichai AU - Khoprasert, Chananan AU - Kesakomol, Piyanate AU - Theeraapisakkun, Montalee AU - Visawapoka, Unchalee PY - 2021/11/09 Y2 - 2024/03/29 TI - ACTIVITY OF TRIAZOLES AND ECHINOCANDINS AGAINST CANDIDA BLOODSTREAM ISOLATES AT PHRAMONGKUTKLAO HOSPITAL, THAILAND JF - Journal of Southeast Asian Medical Research JA - J Southeast Asian Med Res VL - 5 IS - 2 SE - Original Articles DO - 10.55374/jseamed.v5i2.96 UR - https://www.jseamed.org/index.php/jseamed/article/view/96 SP - 84-90 AB - <p><strong>Background:</strong> Candidemia is a major cause of morbidity and mortality which can be treated using antifungal agents, triazoles and echinocandins.</p><p><strong>Objectives:</strong> We aimed to determine <em>Candida</em> species and their sensitivities to triazoles (fluconazole, itraconazole, voriconazole, and posaconazole) and echinocandins (caspofungin, micafungin, and anidulafungin) among patients with candidiasis to guide future treatment of patients with candidemia or invasive candidiasis.</p><p><strong>Methods:</strong> All firstly isolated <em>Candida</em> spp. from patients admitted at Phramongkutklao Hospital, Bangkok, Thailand from January 2012 to December 2013 were included in this study. The antifungal susceptibility testing of Candida spp. isolates was assessed based on micro-dilution method.</p><p><strong>Results:</strong> During the 24-month study period, a total of 66 <em>Candida</em> isolates from 66 patients were identified. Of the 66 isolates, 35 (53%) were <em>C. albicans</em>, 18 (27.3%) were <em>C. tropicalis</em>, 10 (15.2%) were <em>C. glabrata</em> and 3 (4.5%) were <em>C. parapsilosis</em>. Fluconazole resistant Candida isolates were found in <em>C. glabrata</em> (100%), <em>C. albicans</em> (14.3%), <em>C. tropicalis</em> (22.2%) and <em>C. parapsilosis</em> (66.7%). Most <em>Candida</em> spp. isolates were mainly susceptible to echinocandins (&gt;90%). Notably, 10%-20% of C. glabrata isolates showed resistance to echinocandins.</p><p><strong>Conclusion:</strong> Fluconazole, an empirical therapy, has been cautiously used due to resistant non-albicans <em>Candida</em> species especially, <em>C. glabrata</em>, <em>C. tropicalis</em> and <em>C. parapsilosis</em>. However, the emerging echinocandins resistant <em>C. glabrata</em> isolates need to be closely monitored.</p> ER -